Videos

Neuro-oncology experts examined how emerging cancer therapies may reshape the spectrum of paraneoplastic neurologic syndromes. [WATCH TIME: 4 minutes]

Migvis Monduy, MD, provided clinical perspective on how vamorolone compares with traditional corticosteroids and why its safety profile matters in long-term Duchenne management.

Discover emerging imaging techniques and biomarkers for multiple sclerosis that enhance clinical practice and improve patient outcomes.

The neurologist at LMU Munich University Hospital discussed newly published data supporting plasma brain-derived tau as a dynamic biomarker of infarct growth and treatment response in acute ischemic stroke. [WATCH TIME: 4 minutes]

In this episode, the panel reviews the real-world efficacy and safety data from their 176-patient cohort, highlighting relapse risk across therapies, the cumulative safety burden of rituximab, and why mycophenolate mofetil and azathioprine may no longer have a role in NMOSD management.

Neuro-oncology experts discussed best practices for initiating immunomodulatory therapy in patients with PNS, factors influencing neurologic recovery, and the role of early specialty involvement and supportive care in optimizing long-term outcomes. [WATCH TIME: 4 minutes]

New stroke-prevention guidance urges early dual antiplatelets for minor stroke/TIA, faster anticoagulation for AF, and LDL targets plus diet focus.

Clinicians tailor secondary stroke prevention talks by cause, literacy, and resources—boosting adherence through risk-factor coaching, shared decisions, and affordable antithrombotics.

The associate professor of neurology at Mayo Clinic College of Medicine breaks down new real-world INFUSE findings and explains how clinicians should interpret the effectiveness of intravenous eptinezumab in patients with refractory, high-burden migraine. [WATCH TIME: 5 minutes]

A clinician and researcher at the University of California, San Francisco highlighted how agentic AI frameworks are being integrated into real-world multiple sclerosis research to streamline big data analysis and accelerate clinically meaningful discovery. [Watch Time: 5 minutes]

Neuro-oncology experts examined how cumulative neurotoxicity from cytotoxic and targeted therapies can obscure paraneoplastic neurologic syndromes, and how treatment timing and modification decisions influence neurologic outcomes. [WATCH TIME: 6 minutes]

Neurology News Network for the week ending February 28, 2026. [WATCH TIME: 5 minutes]

Experts discuss current imaging techniques and biomarkers for monitoring disease progression in MS, emphasizing the need for improved metrics and awareness.

Neuro-oncology experts discussed how to differentiate classic PNS from immune-related neurologic adverse events, including the impact of prior immunotherapy exposure and the challenge of balancing neurologic stabilization with ongoing cancer treatment. [WATCH TIME: 5 minutes]

Healthcare professionals explore how subtle MS progression impacts daily life and quality of life, emphasizing the importance of targeted assessments.

Shamik Bhattacharyya, MD, and Philippe-Antoine Bilodeau, MD, provide background on their recent Neurology publication, explaining why the study was conducted, how newer FDA-approved NMOSD therapies compare with rituximab, and the complex real-world methods used to assess relapse and safety outcomes.

Neuro-oncology experts outlined screening strategies, antibody testing, and patient factors that help distinguish paraneoplastic neurologic syndromes from treatment toxicity and immune-related events. [WATCH TIME: 6 minutes]

Clinicians explain secondary stroke prevention by tailoring education, addressing risk factors, and choosing affordable antithrombotic plans through shared decision-making to boost adherence.

Stroke recurrence risk peaks in the first days after TIA or minor stroke, driving rapid evaluation and tailored prevention strategies like short-term dual antiplatelet therapy.

The senior research investigator at the New York Stem Cell Foundation answered questions about the research efforts needed to advance iPSC human models toward clinical relevance for patients with multiple sclerosis. [WATCH TIME: 4 minutes]

A duo of neuro-oncologists from Northwestern Medicine explained how to distinguish paraneoplastic neurologic syndromes from treatment toxicity and metastatic disease. [WATCH TIME: 8 minutes]

The head of the Phase I Clinical Research Unit at Beijing Tiantan Hospital discussed positive clinical trial findings for a dual-target neuroprotectant in patients with acute ischemic stroke presented at ISC 2026. [WATCH TIME: 3 minutes]

The professor of medicine at McMaster University discussed findings from OCEANIC-STROKE, where treatment with asundexian reduced the risk of recurrent stroke without increasing major hemorrhage in patients. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending February 21, 2026. [WATCH TIME: 5 minutes]

An associate professor in neurosurgery at Duke University discussed his presentation on novel meningeal immune interactions and interferon signaling in multiple sclerosis at the ACTRIMS Forum 2026. [WATCH TIME: 3 minutes]

Clinicians discuss distinguishing between true progression and pseudo-relapses in MS, emphasizing patient insights and monitoring changes over time.

Experts discuss identifying early signs of disease progression through patient history, symptoms, and innovative monitoring techniques for better care.

A movement disorder specialist at Northwestern Medicine discussed developments in disease-modifying research, adaptive clinical trial designs, and evolving device-based therapies in Parkinson disease. [WATCH TIME: 5 minutes]

The chief medical advisor at the Muscular Dystrophy Association also discussed what he personally is looking forward to at the conference this year. [WATCH TIME: 4 minutes]

A pediatric neurologist at the UCL Institute of Neurology in London, England discussed how pediatric-onset MS is marked by intense inflammation, unique neurodevelopmental considerations, and evolving treatment paradigms at ACTRIMS 2026. [WATCH TIME: 5 minutes]